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Attitudes towards non-invasive prenatal diagnosis among obstetricians in Pakistan: a developing, 23 
Islamic country 24 
 25 
Abstract 26 
Objectives: SWDNHKROGHUV¶YLHZVDUHHVVHQWLDOIRULQIRUPLQJLPSOHPHQWDWLRQstrategies for non-invasive 27 
prenatal testing (NIPT).  Little is known about such views in developing countries.  We explored attitudes 28 
toward NIPT among obstetricians in Pakistan, a developing Islamic country.   29 
Methods: A 35-item questionnaire was distributed and collected at eight events (a national conference and 30 
seven workshops in five cities) for obstetric professionals on advances in fetal medicine.   31 
Results: Responses from 113 obstetrician show positive attitudes towards implementation of NIPT: 95% 32 
agreed prevention of genetic conditions was a necessity and 97% agreed public hospitals should provide 33 
prenatal screening tests.  However, participants also agreed the availability of NIPT would increase social 34 
pressure on women to have prenatal screening tests and to terminate an affected pregnancy (53% and 63%, 35 
respectively).  Most participants would not offer NIPT for sex determination (55%), although 31% would.  36 
The most valued aspects of NIPT was its safety, followed by its utility, then accuracy.   37 
Conclusion: Participants generally supported the implementation of NIPT, but raised concerns about social 38 
implications.  Therefore, national policy is needed to regulate the implementation of NIPT, and pre-test 39 
information and post-test genetic counselling is needed to mitigate social pressure and support parents to 40 
make informed decisions.  41 
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What's Already Known About This Topic?  42 
x Non-invasive prenatal testing (NIPT) is being introduced into private prenatal healthcare in 43 
developing countries. 44 
x SWDNHKROGHUV¶YLHZVDUHHVVHQWLDOIRULQIRUPLQJLPSOHPHQWDWLRQVWUDWHJLHVIRU1,37. 45 
x Little is known about VWDNHKROGHUV¶YLHZVin developing countries. 46 
What Does This Study Add?  47 
x There is a need for a national policy on prenatal screening to regulate the implementation of NIPT. 48 
x Pre-test information and post-test genetic counselling is essential to help mitigate social pressure and 49 
support parents to make informed decisions. 50 
 51 
  52 
  53 
4 
 
Introduction 54 
Non-invasive prenatal testing (NIPT) utilizing cell-free fetal DNA in maternal plasma can be used to test for 55 
fetal trisomies, fetal Rhesus status, sex chromosome disorders and fetal sex and some micodeletions.  56 
Advances in NIPT technologies are resulting in a rapidly expanding range of testable conditions.1  NIPT is 57 
used mainly to test for the common trisomies, particularly trisomy 21 (Down syndrome), either as the initial 58 
screening test, in addition to or instead of combined screening, or as a more accurate test after a high-risk 59 
combined screening result (known as contingent screening).2 Using cell-free fetal DNA, NIPT has high  60 
sensitivity and specificity for Down syndrome, and slightly lower sensitivity for Edwards, and Patau 61 
syndrome.3  However, it is not considered diagnostic because it has a positive predictive value (the chance 62 
that the child will have Down syndrome) of approximately 80%.3,4  Furthermore, the performance of cfDNA 63 
screening tests is depended on fetal fraction (the amount of the cell-free DNA in the maternal blood that is of 64 
fetal origin) and sampling.  For example, uninterpretable and non-reportable CfDNA test results due to low 65 
fetal fraction in patients carrying aneuploid foetuses can range from 1% to 5%, and sampling errors are 66 
reported in 3% and 7% of patients.5  There is also limited evidence about the performance of cfDNA 67 
screening for women of different ethnic origins.6  Therefore, a positive NIPT result would require 68 
confirmatory invasive testing.   69 
NIPT has been commercially available in the USA, parts of Europe, Asia, Africa, Australia and the 70 
Middle East for a number of years.6  It is widely accepted that implementation strategies for NIPT should be 71 
EDVHGRQVWDNHKROGHUV¶YLHZVDQGWhere is much research on the ethical, legal and social implication (ELSIs) 72 
of NIPT,7 generally showing that it is acceptable to various stakeholder.8,9  However, the simplicity, safety, 73 
accuracy and availability of NIPT early in pregnancy raises a number of ethical and social concerns.  These 74 
include higher uptake of testing and without sufficient consideration,10,11 women feeling pressured to 75 
terminate affected pregnancies and normalisation of selective abortions,12,13 potential misuse of the 76 
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technology for less serious or non-medical conditions,14 and diminishing acceptance of people with 77 
disabilities.15-17   78 
Doctors are now introducing NIPT into private prenatal healthcare in developing countries, including 79 
the Islamic republic of Pakistan, where there is comparatively little research on the ELSIs of NIPT to inform 80 
implementation.6,18  Pakistan has a population of over 190 million and is the sixth most populous country in 81 
the world.19  Genetic conditions are common in Pakistan predominantly because of the favoured custom of 82 
consanguineous marriages.20  Research on the prevalence of genetic conditions is lacking in Pakistan, 83 
although beta-thalassaemia major is common.21,22 In Pakistan, only basic prenatal healthcare is provided 84 
through public hospitals, where consultations with doctors are free of charge, but patients may have to pay 85 
for medication and tests, such as routine ultrasound scans (approximately one US Dollar), and there is no 86 
provision of prenatal screening tests.  Down syndrome screening is only offered privately by specifically 87 
trained obstetricians (approximately 15-30 US Dollars).  Screening involves a nuchal translucency scan for 88 
soft markers, such as, fetal nuchal fold thickness, femur length and absence of nasal bone, without any 89 
biomarkers.  Screening is followed by amniocentesis or chorionic villus sampling for patients considered at 90 
high risk of having a child with the condition.  The availability of NIPT enables providers to offer an 91 
additional test that is technically more advanced and accurate to those who can afford it (between 480-900 92 
US Dollars).  3UHQDWDOVFUHHQLQJVHUYLFHVKDYHEHHQDYDLODEOHLQ3DNLVWDQ¶VSULYDWHVHFWRUIRUover two 93 
decades, but there is no national policy governing these services.  However, there are fatwas (religious 94 
rulings) placing responsibility on health professionals to determine conditions for which termination of 95 
pregnancy should be offered, albeit privately.23 96 
Furthermore, research shows that there are differences in VWDNHKROGHUV¶ZRPHQ¶VDQG+3V¶) 97 
preferences for prenatal screening tests between countries, suggesting the need for country specific 98 
approaches to implementing NIPT.24  Research within developing countries is essential because the 99 
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implementation of NIPT is likely to be affected by factors such as low priority at policy level, limited health 100 
resources, competing health priorities, lack of trained health professionals, low literacy rates, and cultural 101 
and religious factors.15,25  +HDOWKSURIHVVLRQDOV¶YLHZVDUHSDUWLFXODUO\LPSRUWDQWEHFDXVHRIWKHLUUROHLQ102 
developing policy and practice guidelines, introducing new technologies into clinical practice, and 103 
supporting patient choices.13  *LYHQWKHSDXFLW\RIUHVHDUFKRQVWDNHKROGHUV¶YLHZVabout NIPT in developing 104 
countries,26 and the recent commercial availability of NIPT in Pakistan, this study aimed to explore the views 105 
of obstetricians in Pakistan about NIPT. 106 
Materials and methods 107 
Questionnaire 108 
A self-completion, structured questionnaire developed by Sayres et al. (2011) to explore the views of 109 
obstetricians¶DWWLWXGHVWRZDUGLPSOHPHQWLQJ1,37LQWKH8QLWHG6WDWHVZDVDGDSWHGIRUWKLVVWXG\27  Items 110 
XQOLNHO\WRZRUNLQ3DNLVWDQZHUHH[FOXGHGVXFKDV³,QVXUDQFHFRPSDQLHVKDYHDQREOLJDWLRQWRIXQG111 
SUHQDWDOWHVWLQJ«´EHcause of the lack of availability of such insurance companies in Pakistan and items 112 
specific to Pakistan were added (sixth to eighth item on Figure 1). The questionnaire was chosen because it 113 
included both attitudes towards prenatal screening tests more generally and towards NIPT, neither of which 114 
have been previously explored with obstetricians in Pakistan.  Our 34-item questionnaire included eight 115 
LWHPVRQSDUWLFLSDQWV¶GHPRJUDSKLFVQLQHRQSUHQDWDOscreening tests in general (using a Likert scale to 116 
assess agreement or disagreement, see Figure 1) and seventeen on NIPT (eleven using a Likert scale ± see 117 
Figures 1 and 2, and 6 using rank ordering ± see Figure 3).  The questionnaire was only available in English, 118 
the language in which medical degrees are taught in Pakistan, hence did not preclude any potential 119 
participants. 120 
 121 
Data Collection 122 
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Ethical approval was granted by the Pakistan Medical Association.  Participants were recruited through eight 123 
events: a two-day national conference in Lahore and seven one-day workshops (three in Lahore and one each 124 
in Islamabad, Faisalabad, Peshawar and 0XOWDQRQ³)HWRPDWHUQDO0HGLFLQH´RUJDQLVHGDQGKRVWHGE\WKH125 
Central Park Medical College (CPMC: Lahore, Pakistan).  The events were designed to update obstetricians 126 
on advances in fetal medicine and included a one-hour session on ³NIPT through Cell-Free Fetal '1$´127 
presented by GM (one of the authors, a retired Consultant in Fetal Medicine (Leeds General Infirmary, UK), 128 
currently a visiting professor at CPMC).  Topics covered in the session included: an introduction to cell-free 129 
fetal DNA (cfDNA); uses of cfDNA; sequencing platform; test scope; sample requirements; reporting of 130 
results and recommended subsequent steps.  None of the events were sponsored.  HJ, YR and GM were 131 
present at all the events. YE was also present except for the events in Peshawar and Rawalpindi. 132 
Following the session on NIPT at each event, attendees were informed about the study and asked to 133 
collect the study information sheet and questionnaire (both in English) from the registration table if they 134 
wished to participate. A member of the research team (HJ, a genetic counsellor at Genetech Laboratory) was 135 
DYDLODEOHDWWKHUHJLVWUDWLRQWDEOHDWHDFKHYHQWWRDQVZHUSRWHQWLDOSDUWLFLSDQWV¶TXHULHVDERXWWKHVWXG\136 
Participants completed the questionnaire individually during the lunch/tea break and returned anonymously 137 
completed questionnaires by leaving them on the registration table.  In total, the eight events were attended 138 
by approximately 240 doctors.  We are unable to calculate the response rate for this study, because of the 139 
way in which the questionnaire was distributed.   140 
Results 141 
Sample Characteristics 142 
One hundred and twenty-five participants completed the questionnaire.  Twelve of these participants were 143 
excluded from the analysis because they had completed less than fifty percent of the questionnaire.  The 144 
remaining 113 participants were all medically trained doctors specialising in obstetrics and gynaecology, and 145 
8 
 
currently practicing in Pakistan, with characteristics comparable to the demographic of doctors in this field in 146 
Pakistan.  Most participants were females (92.9%) and under the age of 36 years (55.8%)3DUWLFLSDQWV¶147 
mean age was 38 + 8 years.  Most participants had been practicing medicine for ten years or less (58.4%).  148 
Participants practiced in public (46%), private (22.1%), public and private (31%), or military (0.9%) 149 
hospitals.  Most participants were not currently offering any prenatal screening tests (58.4%).  Participants 150 
offering prenatal screening tests offered a nuchal translucency tests using ultrasound technology (with no 151 
biomarkers), and four participants also offered NIPT.  See Table 1 for a VXPPDU\RISDUWLFLSDQWV¶152 
demographic characteristics. 153 
[Insert Table 1] 154 
3HUFHSWLRQVRI3UHQDWDO6FUHHQLQJ7HVWV*HQHUDOO\ 155 
0RVWSDUWLFLSDQWVEHOLHYHGWKDWZRPHQZDQWDVPXFKGLDJQRVWLFLQIRUPDWLRQDVSRVVLEOHDERXWWKHLU156 
SUHJQDQF\DQGDJUHHGZLWKZRPHQUHFHLYLQJDOODYDLODEOHSUHQDWDOVFUHHQLQJWHVWVXSRQUHTXHVW157 
DOWKRXJKRISDUWLFLSDQWVGLVDJUHHGVHH)LJXUH7KHPDMRULW\RISDUWLFLSDQWVDJUHHGWKDWSUHQDWDO158 
VFUHHQLQJWHVWUHVXOWVVLJQLILFDQWO\DIIHFWZRPHQ¶VGHFLVLRQVDERXWZKHWKHUWRFRQWLQXHRUWHUPLQDWHD159 
SUHJQDQF\DQGWKDWWKLVZDVDQDSSURSULDWHFRQVHTXHQFHRIWHVWLQJ 3DUWLFLSDQWV¶YLHZVZHUH160 
divided about ZKHWKHUWKHUHZHUHVWURQJVRFLDOSUHVVXUHVRQSUHJQDQWZRPHQWRKDYHSUHQDWDOVFUHHQLQJ161 
ZKHUHRISDUWLFLSDQWVDJUHHGGLVDJUHHGDQGQHLWKHUDJUHHGQRUGLVDJUHHG 162 
0RVWSDUWLFLSDQWVEHOLHYHGWKDWSUHQDWDOVFUHHQLQJZDVDFFHSWDEOHLQ3DNLVWDQDQGSUHYHQWLRQRI163 
JHQHWLFFRQGLWLRQVZDVDQHFHVVLW\1LQHW\-VHYHQSHUFHQWRISDUWLFLSDQWVDOVREHOLHYHGWKDWSXEOLF164 
KRVSLWDOVVKRXOGSURYLGHSUHQDWDOVFUHHQLQJWHVWVWRSUHJQDQWZRPHQDQGDJUHHGWKDWJHQHWLFFRXQVHOOLQJ165 
ZDVDQHFHVVDU\FRPSRQHQWRISUHQDWDOVFUHHQLQJ 166 
[Insert Figure 1] 167 
3HUFHSWLRQVRIWKH,PSOLFDWLRQVRI1,37 168 
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2QO\RISDUWLFLSDQWVDJUHHGWKH\KDGDKLJKOHYHORINQRZOHGJHDERXW1,37GLVDJUHHGDQG169 
QHLWKHUDJUHHGQRUGLVDJUHHG  1HYHUWKHOHVVPRVWSDUWLFLSDQWVDOVREHOLHYHG1,37RIIHUHGYDOXHIRUPRQH\170 
WKDWWKHDYDLODELOLW\RI1,37ZRXOGHQFRXUDJHFOLQLFLDQVWRWHVWPRUHSUHJQDQWZRPHQDQGWKDW171 
WKH\ZRXOGRIIHULWWRWKHLUSDWLHQWV (7HQSHUFHQWRISDUWLFLSDQWVZRXOGQRWRIIHU1,37WRWKHLUSDWLHQWV172 
DQGZHUHXQVXUH±WKHUHZDVQRVLJQLILFDQWGLIIHUHQFHLQUHVSRQVHVEHWZHHQSDUWLFLSDQWVZRUNLQJLQ173 
SXEOLFRUSULYDWHKRVSLWDOV0RVWSDUWLFLSDQWVDFNQRZOHGJHGWKDWZRPHQZHUHXQOLNHO\WRFRQVLGHUWKH174 
LPSOLFDWLRQRI1,37DWWKHWLPHRIWHVWLQJDOWKRXJKZHUHXQVXUHDQGEHOLHYHGWKH\ZRXOG175 
0RVWSDUWLFLSDQWVDOVREHOLHYHGWKDWWKHDYDLODELOLW\RI1,37ZRXOGLQFUHDVHVRFLDOSUHVVXUHRQZRPHQWR176 
KDYHSUHQDWDOVFUHHQLQJDQGWRWHUPLQDWHDQDIIHFWHGSUHJQDQF\DQGUHVSHFWLYHO\ 177 
When asked about offering NIPT for specific conditions, most participants would offer it for Down 178 
syndrome, other aneuploidy/chromosomal anomalies, and Rh blood group (93%, 90%, 86% respectively).  179 
Most participants would not offer NIPT for sex determination (55%), although almost a third of participants 180 
would (31%) and 14% were undecided (see Figure 2). 181 
[Insert Figure 2] 182 
Participants also ranked six key aspects of NIPT in order of their importance, with 1 being most 183 
important to 6 being least important (see Figure 3).  ³1RULVNWRWKHIHWXVDQGPRWKHU´ZDVUDQNHGDVWKHPRVW184 
important aspect of NIPT, with a mean ranking of 2.7 - most frequently ranked as 1 or 2 (23.7% and 36.8%, 185 
respectively).  7KHHDVHRIXVLQJ1,37DVD³VLPSOHEORRGWHVW´ZDVUDQNHGDVWKHVHFRQGPRVW important 186 
aspect of NIPT, with a mean ranking of 3.1 and most frequently ranked as 1 by 25% of participants.  This 187 
was followed by the high accuracy of NIPT (most frequently ranked as 3) and being able to conducted NIPT 188 
in early pregnancy (most frequently ranked as 4), both with a mean ranking of 3.2.  The range of conditions 189 
testable with NIPT was most frequently ranked as 4 or 5, with a mean ranking of 4.1.  The cost of NIPT was 190 
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most frequently ranked as 6 and had the lowest mean ranking (4.7), although a significant minority of 191 
participants ranked this as 1 (13.2%). 192 
[Insert Figure 3] 193 
Discussion 194 
Health professionals play a critical role in the clinical implementation of new technologies.  Participants in 195 
our study believed that most women want as much diagnostic information as possible and that test results 196 
would significantly affect their decision about whether to continue or terminate a pregnancy, yet women 197 
should receive all available prenatal screening tests upon request.  The findings suggest obstetricians support 198 
the prevention of genetic conditions.  This may be due to their XQGHUVWDQGLQJRIZRPHQ¶VGHPDQGIRU199 
prenatal screening tests for various conditions,28 and experiences of the implications for affected families,29 200 
as there is no government provision of medical, social or financial support for such families.30 201 
Just over half of the participants believed that there are strong social pressures on women to opt for 202 
prenatal screening tests.  They also believed that women were unlikely to consider the implications of NIPT, 203 
and that the availability of NIPT would increase social pressure on women to both test and terminate an 204 
affected pregnancy.  ³6ocial pressures´ are most likely to have been interpreted by participants as being due 205 
to cultural and economic implications of having a child with a disability in Pakistan.29,31  For example, 206 
parents of children with Down syndrome may experience stigmatisation, social isolation, and rejection of 207 
themselves and/or their affected child by family and community, where negative cultural beliefs include an 208 
affected child being a divine punishment for parents.29  Pre-test information about the condition and post-test 209 
genetic counselling FRXOGPLWLJDWHSDUHQWV¶IHHOLQJVRISUHVVXUHWRRSWIRU1,37RUWHUPLQDWLRQRI210 
pregnancy.13  However, obstetricians currently offering NIPT in Pakistan provide written information about 211 
the test, but not about the conditions tested for.  Similar to others,32-34 we acknowledge the lack of pre-test 212 
information and genetic counselling as major issues in implementing NIPT, FRPSURPLVLQJSDUHQWV¶213 
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autonomy.  Our findings highlight the importance of clinical guidelines on how NIPT should be provided to 214 
parents, including guidance on (a) pre-test information provision so that parents understand the implications 215 
of testing,34 and (b) provision of post-test genetic counselling for parents at high risk of having an affected 216 
child to enable them to make informed decisions about invasive testing and termination of pregnancy. 217 
Similar to others,35 most of the participants believed that genetic counselling is a necessary 218 
component of prenatal screening.  However, we acknowledge the challenges of providing pre- and post-test 219 
genetic information for NIPT in a developing country like Pakistan, because of its low literacy rate and the 220 
lack of government funded prenatal screening or genetic services.  Also, in developed countries, midwives 221 
and genetic counsellors/prenatal counselling specialists are usually responsible for the provision pre- and 222 
post-test counselling, respectively. However, in developing countries, this responsibility is most likely to be 223 
WKHREVWHWULFLDQV¶Furthermore, less than a third of the obstetricians in our study believed they had a high 224 
level of knowledge of NIPT even after a one-hour session on this topic:KLOVWZHDFNQRZOHGJHWKDWµDKLJK225 
OHYHORINQRZOHGJH¶LVVXEMHFWLYH, this ILQGLQJPD\LQGLFDWHSDUWLFLSDQWV¶perceptions of their limited ability 226 
to fully understand NIPT, which in turn may be related to poor knowledge on genetics.  Therefore, there is a 227 
need for basic genetic education for obstetricians,13,36 but also for research in developing countries to explore 228 
the most amenable and efficient means of providing pre-/post-test counselling for NIPT.   229 
Similar to Pakistan, other developing counties are also likely to lack public hospital infrastructures 230 
for prenatal screening and genetic services.  Nevertheless, given the commercial availability of NIPT, with 231 
the potential for testing for a range of conditions, and in light of other genetic technologies likely to be 232 
available in developing countries in the near future (whole genome sequencing), health professionals will 233 
need to be able to translate information for more complicated test results.  Therefore, efforts should be made 234 
to ensure that obstetricians have basic genetic education and training in key aspect of genetic counselling.13   235 
12 
 
Moreover, participants almost unanimously agreed that public hospitals should provide prenatal 236 
screening tests to pregnant women.  Overall, the interest in the prevention of genetic conditions in this 237 
Muslim country highlights the need for debate at policy level to consider (a) strategies for regulating prenatal 238 
genetic technologies in the private sector, and (b) implementing a national antenatal screening policy.37 239 
The majority of doctors would offer NIPT for Down syndrome, other aneuploidy/chromosomal 240 
anomalies and Rh blood group.  This may be because prenatal screening and diagnostic tests are already 241 
available privately for these conditions in Pakistan and termination of pregnancy is acceptable for various 242 
conditions.28,29,38  Given the emphasis on doctors in Islamic states to decide the conditions for which prenatal 243 
screening, diagnostic tests and termination should be available,23 further research should explore 244 
REVWHWULFLDQV¶DWWLWXGHVWRZDUGDODUJHUUDQJHRIFRQGLWLRQVLQFOXGLQJWKRVHIRUZKLFKSUHQDWDOscreening is 245 
not currently available or conditions that could be considered less serious.  Such research would inform the 246 
future implementation of more advanced genetic technologiesVXFKDVµ*HQRPH-ZLGH1,37¶ZKLFKLVOLNHO\247 
to test for more conditions, including less serious and non-medical conditions.39  Approximately a third of 248 
doctors were unsure or would not offer NIPT.  This may be because NIPT was believed to be too expensive, 249 
and offering it to patients may make them appear interested in profit rather than patient care; and/or because 250 
NIPT would still potentially be followed by invasive diagnostic testing.40  Further research is needed on 251 
reasons for this finding. 252 
The availability of NIPT sex testing enables doctors to identify X-linked conditions, not to offer 253 
termination of pregnancy on the grounds of sex alone.  Accordingly, most obstetricians in our study would 254 
not offer NIPT for sex determination, but a significant minority would.  The latter finding may be because 255 
the preference for male children is deeply embedded in Pakistani culture,41,42 yet doctors are not concerned 256 
about the possibility of sex selection leading to an imbalance of sex ratio to males, as observed in countries 257 
like China and India, because abortion on social grounds (including fetal sex) is illegal in Pakistan, 258 
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rHOLJLRXVO\LPSHUPLVVLEOHXQOHVVWKHPRWKHU¶VOLIHLVWKUHDWHQHGDQGculturally disapproved.42  Nevertheless, 259 
our finding raise concerns about the potential use of NIPT for sex determination and further highlight the 260 
importance of national policy to regulate the implementation of NIPT for medical purposes only.13 261 
Most studies in developed countries show that health professionals value the accuracy and timing of 262 
NIPT, while women place greater emphasis on test safety and information.24,43-46 Participants in our study 263 
emphasised test safety, similar to women in developed countries,13,33,46,47 followed by ease of the test (simple 264 
blood test) and then accuracy.  Given the differences in research in developed countries between health 265 
professionals and women, it is important to conduct similar research with women and their partners in 266 
developing countries to ensure that implementation of NIPT also incorporates their needs and preferences. 267 
Surprisingly, the cost of the test was given little importance.  This may be because the cost would be 268 
to the patient and not to health services, because women are already expected to pay for prenatal screening 269 
test, or because of the financial incentives for private prenatal services.  Nevertheless, this raises concerns 270 
about the provision of inequitable health services, where only those with financial resources can afford 271 
prevention of genetic conditions using prenatal screening.48  This further highlights the importance of 272 
national screening programmes in developing countries to ensure that less privileged families are not further 273 
disadvantaged by lack of access to genetic technologies.  274 
The findings should be interpreted with caution as our study was conducted in a large but specific 275 
geographical area with a convenience sample of obstetricians with interest in advances in their field.  276 
Participants were self-selected, therefore, may have had a positive bias towards NIPT.  Also, they completed 277 
the questionnaire after a conference/workshop which included a one-hour session on NIPT, which may have 278 
skewed the findings toward a greater interest in NIPT.  A study capturing the views of participants nation-279 
wide and in other developing countries could further enhance our understanding of the ethical and social 280 
implication of NIPT.  Nevertheless, this study is the first to explore the views of obstetricians about NIPT in 281 
14 
 
a developing, Islamic country.  Qualitative research approaches could provide a more in-depth understanding 282 
of the reasons for the views expressed by the obstetricians in this study.  Furthermore, research is needed 283 
with a wider range of stakeholders, including the views of service users and individuals responsible at a 284 
policy level for regulating and developing guidelines for the use of genetic technologies.  Nevertheless, our 285 
study with obstetricians highlights the importance of various important points for implementing NIPT in 286 
developing countries. 287 
Participants generally supported the introduction of publically funded prenatal screening and the 288 
implementation of NIPT for various conditions, but raised concerns about social implications.  They also 289 
highlight the educational and training needs of obstetric professionals and the importance of developing an 290 
infrastructure for the provision of patient information and genetic counselling to mitigate social pressure and 291 
support women to make informed reproductive choices. 292 
 293 
 294 
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